897661-99-3

Basic information

• Product Name: Thieno[2,3-d]pyridazin-7(6H)-one, 2-(4-chlorophenyl)-
• CAS NO: 897661-99-3
• Molecular Formula: C12H7ClN2OS
• Molecular Weight: 262.719
• Mol File: 897661-99-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Thieno[2,3-d]pyridazin-7(6H)-one, 2-(4-chlorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Thieno[2,3-d]pyridazin-7(6H)-one, 2-(4-chlorophenyl)-(897661-99-3)
• EPA Substance Registry System: Thieno[2,3-d]pyridazin-7(6H)-one, 2-(4-chlorophenyl)-(897661-99-3)

Safety Data

• Hazardous Substances Data: 897661-99-3(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 40133-14-0 5-(4-chlorophenyl)thiophene-2-carboxylic acid 
• 921592-97-4 5-(4-chlorophenyl)-3-formylthiophene-2-carboxylic acid 
• 897661-92-6 4-chloro-2-(tetrahydropyran-2-yl)-5-(4-chlorophenylethynyl)-2H-pyridazin-3-one 

Downstream Products

• 1073282-29-7 2-(4-Chlorophenyl)-6-(4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl)-thieno[2,3-d]pyridazin-7(6H)-one 

Relevant articles and documents

NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS

The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I where R1, R1a, R1b, A, R3, R4, R5, R5b and R6 are as defined herein.

THERAPEUTIC AGENTS

Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.